Abstract
With the advent new proteasome inhibitors (carfilzomib, ixazomib), new immune-modulatory drugs (pomalidomide), and new monoclonal antibodies (elotuzimab, daratumumab) as approved treatments for myeloma, the therapeutic landscape for this disease has changed. In this chapter, using a case-based approach, I will provide a personal guide of how I approach myeloma therapy in a transplant eligible patient in 2018.
© 2018 by The American Society of Hematology. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Back Pain / blood
-
Back Pain / diagnosis
-
Back Pain / diagnostic imaging
-
Back Pain / drug therapy
-
Female
-
Humans
-
Ibuprofen / administration & dosage
-
Immunologic Factors / therapeutic use
-
Lumbar Vertebrae / diagnostic imaging
-
Magnetic Resonance Imaging
-
Middle Aged
-
Multiple Myeloma / blood
-
Multiple Myeloma / diagnosis*
-
Multiple Myeloma / diagnostic imaging
-
Multiple Myeloma / drug therapy*
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Thoracic Vertebrae / diagnostic imaging
-
Tomography, X-Ray Computed
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunologic Factors
-
elotuzumab
-
daratumumab
-
Thalidomide
-
pomalidomide
-
Ibuprofen